| 000 | 01090 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250515135602.0 | ||
| 264 | 0 | _c20090112 | |
| 008 | 200901s 0 0 eng d | ||
| 022 | _a1744-7666 | ||
| 024 | 7 |
_a10.1517/14656566.9.15.2617 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aModlin, I M | |
| 245 | 0 | 0 |
_aPharmacotherapy of neuroendocrine cancers. _h[electronic resource] |
| 260 |
_bExpert opinion on pharmacotherapy _cOct 2008 |
||
| 300 |
_a2617-26 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xtherapeutic use |
| 650 | 0 | 4 |
_aLiver Neoplasms _xsecondary |
| 650 | 0 | 4 |
_aNeuroendocrine Tumors _xdrug therapy |
| 700 | 1 | _aKidd, M | |
| 700 | 1 | _aDrozdov, I | |
| 700 | 1 | _aSiddique, Z-L | |
| 700 | 1 | _aGustafsson, B I | |
| 773 | 0 |
_tExpert opinion on pharmacotherapy _gvol. 9 _gno. 15 _gp. 2617-26 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14656566.9.15.2617 _zAvailable from publisher's website |
| 999 |
_c18271238 _d18271238 |
||